Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Barriers to the Adoption of Healthy Lifestyle Behaviors in Patients With Cancer: Results of a National Survey.

JCO oncology practice·2026

Same author

Prognostic Factors in Limited-Stage Small Cell Lung Cancer: A Secondary Analysis of CALGB 30610-RTOG 0538.

JAMA network open·2024

Same author

Non-invasive detection of orthotopic human lung tumors by microRNA expression profiling of mouse exhaled breath condensates and exhaled extracellular vesicles.

Extracellular vesicles and circulating nucleic acids·2024

Same author

The Inherited KRAS-variant as a Biomarker of Cetuximab Response in NSCLC.

Cancer research communications·2023

Same author

Validation of Immunotherapy Response Score as Predictive of Pan-solid Tumor Anti-PD-1/PD-L1 Benefit.

Cancer research communications·2023

Same author

Attention to diet, exercise, and weight in oncology care: Results of an American Society of Clinical Oncology national patient survey.

Cancer·2022

Search research articles

Related Experiment Video

Updated: Mar 29, 2026

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

Epithelioid inflammatory myofibroblastic sarcoma: a case report.

Daniel E Sarmiento¹, Jessica A Clevenger¹, Gregory A Masters¹

¹1 Department of Surgery, 2 Department of Pathology, Christiana Care Health System, Newark, DE 19718, USA ; 3 Department of Medical Oncology, 4 Department of Thoracic Surgery, Helen F. Graham Cancer Center & Research Institute, Newark, DE 19713, USA.

Journal of Thoracic Disease

|December 2, 2015

Summary

Epithelioid inflammatory myofibroblastic sarcoma (EIMS), a rare lung malignancy, showed significant response to ALK-targeted therapy. This targeted approach offers a promising treatment for EIMS patients with ALK gene rearrangement.

Keywords:

Pleura gene polymorphism sarcoma

More Related Videos

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Tissue Engineering of Tumor Stromal Microenvironment with Application to Cancer Cell Invasion

Tissue Engineering of Tumor Stromal Microenvironment with Application to Cancer Cell Invasion

Published on: March 18, 2014

Related Experiment Videos

Last Updated: Mar 29, 2026

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Author Spotlight: Anterior HR-OCT as a Non-Invasive Tool for Characterizing Ocular Surface Squamous Neoplasia

Published on: August 9, 2024

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Refined Murine Model of Idiopathic Pulmonary Fibrosis

Published on: June 17, 2025

Tissue Engineering of Tumor Stromal Microenvironment with Application to Cancer Cell Invasion

Tissue Engineering of Tumor Stromal Microenvironment with Application to Cancer Cell Invasion

Published on: March 18, 2014

Area of Science:

Oncology
Genetics
Pathology

Background:

Inflammatory myofibroblastic tumor (IMT) is a rare lung malignancy with variable clinical behavior.
Epithelioid inflammatory myofibroblastic sarcoma (EIMS) is a malignant variant of IMT, often affecting young individuals.

Observation:

A case of pleural EIMS initially treated with surgery and chemotherapy is presented.
The tumor exhibited an anaplastic lymphoma kinase (ALK) gene rearrangement.

Findings:

Treatment with an ALK-directed tyrosine kinase inhibitor resulted in an impressive and sustained remission.
This highlights the efficacy of targeted therapy in EIMS with ALK alterations.

Implications:

ALK-targeted therapy represents a potential breakthrough for managing EIMS.
Further research into the pathogenesis and targeted treatment of EIMS is warranted.